Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
Submitted by
admin
on September 6, 2021 - 9:03pm
Source:
Motley Fool
News Tags:
Vertex Pharmaceuticals
CRISPR
gene editing
Arbor Biotechnologies
Headline:
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
snippet:
Arbor Biotechnologies recently announced an expanded collaboration with Vertex to develop CRISPR gene-editing therapies.
The deal is worth up to $1.2 billion, but the amount of any up-front payment from Vertex wasn't revealed.
Do Not Allow Advertisers to Use My Personal information
